Product Program year 2025 Source: CMS Open Payments

Vaprisol Dextrose in Plastic Container

Drug Nephrology

NDC 66220-160-10

Open in the dashboard

General payments

$700,818

272 payments

Research payments

$0

0 payments

Through program year 2025, $700,818 in general payments and $0 in research payments were reported against Vaprisol Dextrose in Plastic Container (Nephrology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

6 rows
Year Kind Amount Payments
2025 General $144,900 28
2024 General $135,542 20
2023 General $141,896 28
2022 General $132,630 51
2021 General $134,733 73
2020 General $11,118 72

Breakdown

Who paid General payments · program years 2020–2025
  1. Cumberland Pharmaceuticals, Inc. $700,818 272 payments
Top recipients General payments · program year 2025
  1. Gordon Bernard Critical Care Medicine · Nashville, TN $100,000 69% · 12 payments
  2. Todd Rice Critical Care Medicine · Nashville, TN $35,900 25% · 13 payments
  3. Nikhil Bhayani Infectious Disease · Bedford, TX $7,000 5% · 1 payment
  4. Bennett Deboisblanc Pulmonary Disease · New Orleans, LA $1,000 <1% · 1 payment
  5. Robert Roberts Cardiovascular Disease · Phoenix, AZ $1,000 <1% · 1 payment

Each share is of general payments naming this product in 2025.

Specialties paid General payments · program year 2025
  1. Critical Care Medicine Internal Medicine $135,900 94% · 2 practitioners
  2. Infectious Disease Internal Medicine $7,000 5% · 1 practitioner
  3. Pulmonary Disease Internal Medicine $1,000 <1% · 1 practitioner
  4. Cardiovascular Disease Internal Medicine $1,000 <1% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2025
  1. Tennessee $135,900 94% · 2 recipients
  2. Texas $7,000 5% · 1 recipient
  3. Arizona $1,000 <1% · 1 recipient
  4. Louisiana $1,000 <1% · 1 recipient

Each share is of general payments naming this product in 2025 where a state was reported.

272 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record